Abstract
Using techniques developed for the study of muscarinic cholinergic receptors in brain homogenate, direct binding to whole live neutrophils has been shown for the potent muscarinic antagonist [3H]quinuclidinyl-benzilate. The specific binding is saturable, proportional to cell concentration, and can be displaced by atropine, oxotremorine, and piocarpine. The Kd for this system is approximately 8 nM. This whole-cell binding correlates with previously reported effects of cholinergic agents on neutrophil guanosine cyclic 3',5'-monophosphate levels, chemotaxis, and lysosomal enzyme release. Quinuclidinyl-benzilate is shown here to function as a muscarinic antagonist in neutrophils by blocking the carbachol stimulated lysosomal enzyme release in vitro from live cells.
ACKNOWLEDGMENTS We wish to thank Ms. Nannette A. Schwartzman from Dr. Peter Henson’s laboratory for invaluable discussion of lysosomal enzyme release techniques.
- Copyright © 1979 by Academic Press, Inc.
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|